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Abstract The administration of tetradecylthioacetic acid
(TTA), a hypolipidemic and anti-inﬂammatory modiﬁed
bioactive fatty acid, has in several experiments based on
high fat diets been shown to improve lipid transport and
utilization. It was suggested that increased mitochondrial
and peroxisomal fatty acid oxidation in the liver of Wistar
rats results in reduced plasma triacylglycerol (TAG) levels.
Here we assessed the potential of TTA to prevent tumor
necrosis factor (TNF) a-induced lipid modiﬁcations in
human TNFa (hTNFa) transgenic mice. These mice are
characterized by reduced b-oxidation and changed fatty
acid composition in the liver. The effect of dietary treat-
ment with TTA on persistent, low-grade hTNFa overex-
pression in mice showed a beneﬁcial effect through
decreasing TAG plasma concentrations and positively
affecting saturated and monounsaturated fatty acid pro-
portions in the liver, leading to an increased anti-inﬂam-
matory fatty acid index in this group. We also observed an
increase of mitochondrial b-oxidation in the livers of
TTA treated mice. Concomitantly, there were enhanced
plasma levels of carnitine, acetyl carnitine, propionyl
carnitine, and octanoyl carnitine, no changed levels in
trimethyllysine and palmitoyl carnitine, and a decreased
level of the precursor for carnitine, called c-butyrobetaine.
Nevertheless, TTA administration led to increased hepatic
TAG levels that warrant further investigations to ascertain
that TTA may be a promising candidate for use in the
amelioration of inﬂammatory disorders characterized by
changed lipid metabolism due to raised TNFa levels.
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Chronic low-grade inﬂammation accompanies the devel-
opment of metabolic syndrome features, like abdominal
obesity, dyslipidemia, hypertension, and insulin resistance,
known risk factors for cardiovascular disease affecting
millions of people worldwide. The ﬁrst indication that there
is a connection between obesity, diabetes and chronic
inﬂammation came from the observation that the pro-
inﬂammatory cytokine tumor necrosis factor (TNF) a is
overexpressed in adipose tissues of obese mice and humans
[1, 2]. Moreover, its inactivation with anti-TNFa antibodies
improved insulin resistance in obese mice [2], whereas
TNFa null mice would not develop insulin resistance after
diet-induced obesity [3]. The multifunctional cytokine
TNFa was shown thereafter to perturb lipid metabolism by
increasing free fatty acid production [4, 5], promoting
lipolysis [6–9], affecting lipid-metabolism-related gene
expression [10, 11], controlling cholesterol metabolism
[12, 13], and inﬂuencing expression and secretion of other
adipokines [14–17].
Used as a model for persistent low-grade TNFa expo-
sure, we have found previously that hTNFa transgenic
mice show a down-regulation of peroxisome proliferator-
activated receptor (PPAR) a target genes [18]. The mito-
chondrial enzymes involved in hepatic lipid metabolism
were inﬂuenced, leading to changes in fatty acid synthesis
and oxidation [18]. In particular, not only carnitine pal-
mitoyltransferase-I and -II (CPT-I and -II), proteins
important for the b-oxidation of long-chain fatty acids in
mitochondria, but also fatty acyl-CoA oxidase (FAO),
which is important for peroxisomal b-oxidation, proved to
have decreased hepatic activity in the hTNFa transgenic
mice [18]. In addition, TNFa overexpression was associ-
ated with a signiﬁcant reduction of hepatic mRNA levels of
mitochondrial HMG-CoA synthase, the rate-limiting
enzyme in ketogenesis [18]. Moreover, lipogenesis is
affected by TNFa. Namely, the two important enzymes in
lipogenesis, acetyl-CoA carboxylase (ACC), which pro-
duces malonyl-CoA for fatty acid synthesis, showed a
tendency for lowered activity, whereas fatty acid synthase
(FAS), an enzyme involved in long-term regulation of fatty
acid synthesis, displayed a signiﬁcantly decreased activity
[18].
As lipids have the ability to modulate metabolic,
inﬂammatory and innate immune processes [19], we
investigated in the present study, whether the fatty acid
analogue tetradecylthioacetic acid (TTA) could counteract
the health risks as a consequence of TNFa-overexpression.
To be able to investigate inﬂammation in relation to lipid
accumulation as seen in the nutritional disorder of obesity,
we chose to administer a high-fat diet. TTA is a saturated
fatty acid containing 16 carbons and one sulfur atom at
position three of the carbon chain from the alpha end, a
characteristic that results in its increased metabolic stability
[20]. TTA is known to act, at least partly, through the
activation of PPAR [21–23], and inﬂuence plasma lipids by
increasing hepatic b-oxidation [24, 25]. Moreover, we have
reported that TTA has antioxidant and antiinﬂammatory
properties [26].
In the present work, we show that the administration of
TTA to hTNFa transgenic mice fed a high-fat diet showed
beneﬁcial effects on serum cholesterol and triacylglycerol
(TAG) levels, hepatic fatty acid composition and choles-
terol levels, with a concurrent increase in hepatic b-oxi-
dation and fatty inﬂammatory index.
Experimental Procedure
Transgenic Mice
The study was performed on female transgenic mice
expressing low levels of human TNFa (hTNFa) mice from
Taconic (Germantown, USA). The transgenic mouse line
was generated in strain C57Bl/6 [27]. The experiments
were performed in accordance with, and under the approval
of, the Norwegian State Board for Biological Experiments,
the Guide for the Care and Use of Laboratory Animals, and
the Guidelines of the Animal Welfare Act. The mice were
between 6 and 8 weeks of age at the start of the experi-
mental feeding and were divided into two experimental
groups of ﬁve animals each with comparable mean body
weight. They were housed in cages with constant temper-
ature (22 ± 2 C) and humidity (55 ± 5%), where they
were exposed to a 12 h light-dark cycle (light from 07.00
to 19.00) and had unrestricted access to tap water and food.
The mice were acclimatized to these conditions before the
start of the experiment.
Protein and fat of the feeding diets were from casein
sodium salt from bovine milk, 20% (Sigma-Aldrich Nor-
way AS, Oslo, Norway) and lard, 23% (Ten Kate Vetten
BV, Musselkanaal, Netherlands) plus soy oil, 2% (Dyets
Inc., Bethlehem, PA, USA). In addition, in the TTA group
0.6% of the lard was substituted by TTA. The TTA was
synthesized as described earlier [28]. There were no sig-
niﬁcant differences in fatty acid composition between
control and TTA diets, except the TTA content (SFA 43.9
vs. 42.8 wt%, MUFA 38.8 vs. 37.8 wt%, PUFAn-3 1.51 vs.
1.48 wt%, PUFAn-6 15.6 vs. 15.3 wt%, TTA 0.0 vs 2.5
wt%).
The mice were anaesthetized under fasting conditions by
inhalation of 2% isoﬂurane (Schering-Plough, Kent, UK)
after two weeks of feeding. Blood was collected by aortic
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123puncture with 7.5% EDTA and immediately chilled on ice.
Plasma was prepared and stored at -80 C prior to anal-
ysis. Parts of the liver were used for b-oxidation analysis
and chilled on ice, and the rest was freeze-clamped and
stored at -80 C until the analysis of fatty acids, triacyl-
glycerols, cholesterol, and enzyme activities.
Plasma and Hepatic Lipids
Liver lipids were extracted according to Bligh and Dyer
[29], evaporated under nitrogen, and redissolved in iso-
propanol before analysis. Lipids were subsequently mea-
sured enzymatically on a Hitachi 917 system (Roche
Diagnostics GmbH, Mannheim, Germany) using the tri-
acylglycerol (GPO-PAP) and cholesterol kit (CHOD-PAP)
from Roche Diagnostics (Mannheim, Germany) and the
phospholipid kit from bioMe ´rieux SA (Marcy l’Etoile,
France).
Hepatic Fatty Acid and Plasma Carnitine Compositions
Total hepatic fatty acid composition was analyzed as
described previously [18]. The anti-inﬂammatory fatty acid
index was calculated as (docosapentaenoic acid ? doco-
sahexaenoic acid ? dihomo-c-linolenic acid ? eicosapen-
taenoic acid)x100/arachidonic acid. Slightly different
indexes have been used by [30, 31]. Free carnitine, short-,
medium-, and long-chain acylcarnitines, and the precursors
for carnitine, trimethyllysine and c-butyrobetaine, respec-
tively, were analysed in plasma using HPLC/MS/MS
as described previously [32] with some modiﬁcations
(Svardal et al., in preparation).
Hepatic Enzyme Activities
The livers were homogenized and fractionated as described
earlier [33]. Palmitoyl-CoA oxidation was measured in a
mitochondria-enriched extract from liver as acid-soluble
products [34]. The activities of carnitine palmitoyltrans-
ferase (CPT)-I [35] and acyl-CoA synthetase (ACS) [35]
were measured in the mitochondrial fraction. Fatty acid
synthase (FAS) was measured in the post-nuclear fraction
as described by Skorve et al. [36].
Statistical Analysis
Data sets were analyzed using Prism Software (Graph-Pad
Software, San Diego, CA) to generate the ﬁgures and
determine statistical signiﬁcance. The results are shown as
means with their standard deviations (S.D.). A t-test was
used to determine signiﬁcant differences between the
control and the TTA treatment group. P-values\0.05
were considered signiﬁcant.
Results
Body/Liver Weights and Feed Intake
We found that TTA supplementation for two weeks to
hTNFa-overexpressing mice promoted a signiﬁcant
decrease in body weights (-0.8 ± 0.8 g) as compared to
high-fat-fed control animals (1.4 ± 0.6 g) (Table 1).
Whereas liver weights and liver index were signiﬁcantly
increased in the TTA supplemented group (1.4 ± 0.09 and
7.2 ± 0.43) in comparison to the control group (0.9 ± 0.08
and 4.3 ± 0.3). The TTA group displayed a reduced total
feed intake, 30 g versus 34 g of diet per TTA- or control-
fed mouse, respectively. Thus, the TTA group seems more
efﬁcient in converting feed into increased body mass, as
shown by a lower total feed efﬁciency (-0.03) in com-
parison to the control group (0.04).
Serum and Hepatic Lipids
In previous studies, comparing transgenic hTNFa-over-
expressing with wildtype mice, TNFa interfered with lipid
metabolism, leading to increased hepatic TAG and total
cholesterol levels. Serum cholesterol concentrations were
decreased, whereas serum TAG levels were unchanged
[18].
In this study, two weeks of 0.6% TTA administration
promoted positive effects on plasma parameters in hTNFa-
overexpressing mice fed a high fat diet. The transgenic
mice showed increased levels of total cholesterol due to a
39% increase in HDL-cholesterol in the TTA treated group
(Fig. 1a) as compared to the high fat-fed controls. With
regard to plasma TAG, a drastic reduction of 54% was
observed after TTA treatment (Fig. 1b) as compared to the
control. Plasma phospholipids (Fig. 1c) and free fatty acids
(data not shown) were not signiﬁcantly changed. The
hepatic levels of total cholesterol showed a non-signiﬁcant
tendency to decrease in the TTA-treated group (Fig. 1d),
and the already high TAG amounts in transgenic mice
Table 1 Body and liver weights, liver index [100 9 (liver weight in
g/body weight in g)], total feed intake, and feed efﬁciency (weight
gain in g/food intake in g)
Control TTA
Initial body weight (g) 19.2 ± 1.1 20.2 ± 1.3
Final body weight (g) 20.6 ± 1.5 19.4 ± 1.3
Body weight gain (g) 1.4 ± 0.6 -0.8 ± 0.8
Liver weight (g) 0.9 ± 0.08 1.4 ± 0.09
Liver index 4.3 ± 0.3 7.2 ± 0.43
Total feed intake (g) 34.2 30
Total feed efﬁciency 0.04 -0.03
Values are mean ± S.D. (n = 5)
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123further increased after TTA treatment (Fig. 1e). The
hepatic phospholipid level was also elevated after TTA
administration in comparison to control mice (Fig. 1f).
Fatty Acid Composition in Liver
In order to investigate if the results obtained for hepatic
lipids were speciﬁc for cholesterol and TAG or if fatty
acids were also affected signiﬁcantly, we performed an
analysis of the total hepatic fatty acid composition. We
have previously demonstrated an increased weight % of
saturated fatty acids (SFAs) in TNFa-overexpressing mice
on a chow diet [18].
Here we observed a comparable level of SFAs in TNFa-
overexpressing mice (in spite of higher dietary SFA con-
tent in the high-fat diet used- see Discussion). TTA treat-
ment lead to decreased weight % in saturated fatty acid
levels (Fig. 2a). The most signiﬁcant individual decreases
could be found in the fatty acids C15:0, C17:0, C18:0,
C22:0, C23:0, and C24:0 (Table 2). The most impact on
decreasing total SFAs had C18:0.
The relative amounts of monounsaturated fatty acids
(MUFA) that were shown to be decreased in hTNFa
transgenic in comparison to wildtype mice [18], were
signiﬁcantly increased by TTA in the diet (Fig. 2b). This
was mainly due to the increased amount of oleic acid
(C18:1n-9) that was to some extent induced by increased
D9 desaturase activity as the index D9 desaturase activity
suggests (Table 2).
A signiﬁcant decrease in weight % of n-3 and n-6
polyunsaturated fatty acids (PUFA) was observed in the
transgenic mice treated with TTA (Fig. 2c and d) when
compared to control animals. This was reﬂected in
decreased amounts of the n-3 PUFA alpha-linolenic acid
(18:3n-3), stearidonic acid (C18:4n-3) and docosahexae-
noic acid (C22:6n-3), along with linoleic acid (C18:2n-6)
and arachidonic acid (C20:4n-6) that can mainly be
attributed to lowered levels of n-6 PUFA (Table 1). The
sums result in a decreased ratio of n-3 to n-6 PUFA
(Table 1). TTA seems to counteract the increased PUFA
levels seen in transgenic mice in contrast to wildtype mice
that were due to increased weight % of n-3, with
unchanged n-6 levels, giving an increased n-3 to n-6 ratio
[18].
In addition, after TTA administration, there was a strong
decrease in the C20:4n-6/C20:3n-6 ratio as an indirect
measure of the n-6 D5 desaturase activity, an enzyme
important for the production of arachidonic acid (Table 2).
This indicates that TTA might decrease the hepatic desat-
uration of dihomo-c-linolenic acid (20:3n-6) to arachidonic
acid (20:4n-6) in hTNFa transgenic mice. Whereas
beforehand, we observed increased ratios pointing towards
increased activities of D6 and D5 desaturases in transgenic
mice in comparison to control animals [18].
Fig. 1 TTA treatment induces a signiﬁcant increase in plasma HDL-
cholesterol levels in hTNFa transgenic mice (a) and a decrease in
plasma TAG levels (b), whereas phospholipids showed no change (c).
Hepatic cholesterol showed no signiﬁcant change (d), but a TAG and
phospholipid-increasing effect in the liver was found after treatment
with TTA (e, f). Data are means ± S.D. (n = 5). * denotes statistical
signiﬁcant differences by Student’s t-test between control (grey bars)
and TTA (white bars)( P\0.05). chol, cholesterol; HDL, high-
density lipoprotein; LDL, low density lipoprotein; PL, phospholipid;
AG, triacylglycerol; TTA, tetradecylthioacetic acid
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(docosapentaenoic acid ? docosahexaenoic acid ? diho-
mo-c-linolenic acid ? eicosapentaenoic acid) 9 100/ara-
chidonic acid [30], increased after TTA treatment.
Hepatic b-Oxidation of Fatty Acids
The TAG-lowering effect observed in plasma of hTNAa
transgenic mice after TTA treatment, could be due to an
enhancedmitochondrialandperoxisomal b-oxidationthat is
responsiblefortheshorteningoflong-chainfattyacyl-CoAs.
Indeed, b-oxidation increased by 48% in the TTA treated
mice, when using
14C-palmitoyl-CoA as substrate (Fig. 3a),
counterbalancing the decreased b-oxidation values from
transgenic mice [18]. In the previous study, the sensitivity
towardsmalonyl-CoA,aninhibitorofCPT-I,wasunaffected
by TNFa [18]. However, in the TTA treated group we
detected a lowering of the inhibition capacity of malonyl-
CoA from 35% to 14% inhibition (Fig. 3b) and the transport
of fatty acids across the mitochondrial outer membrane is
facilitated even in the presence of malonyl-CoA.
Activities of Enzymes Involved in Degradation
and Biosynthesis of Fatty Acids
In order to explain the mechanisms of TTA in more detail,
enzyme activities were measured in the post-nuclear frac-
tion of the liver. The enzymatic activity of CPT-I, the rate-
limiting enzyme of mitochondrial b-oxidation, involved in
acyl group transport into the matrix, was increased after
TTA treatment (Fig. 4a). Likewise, the mitochondrial
enzyme acyl-CoA synthetase (ACS) that activates fatty
acids prior to oxidation, showed increased activity
(Fig. 4b). On the other hand, a major cytosolic, multi-
functional enzyme involved in the biosynthesis of fatty
acids, called fatty acid synthase (FAS), showed reduced
activity (Fig. 4c).
Oxidation of fatty acids can be facilitated not only by
the up-regulation of CPT-I, but also by an increased con-
centration of its substrate carnitine, to ensure efﬁcient
transport of fatty acids into mitochondria. Carnitine can be
taken up from dietary sources or is endogenously synthe-
sized primarily in the liver and kidney [37, 38]. All other
tissues have to take carnitine actively up from the blood.
We found that in plasma, free carnitine concentrations have
increased during TTA treatment by 36% in comparison to
control animals (Fig. 5a). The precursors for carnitine,
were either unchanged (trimethyllysine, Fig. 5b) or
reduced (c-butyrobetaine, Fig. 5c). The two quantitatively
most important acyl-esters, acetyl carnitine (Fig. 5d) and
propionyl carnitine (Fig. 5e) were signiﬁcantly increased
by TTA compared to high fat-fed controls. The plasma
medium-chain acylcarnitine, octanoyl carnitine, was sig-
niﬁcantly increased (Fig. 5f) and the long-chain acylcar-
nitine, palmitoyl carnitine, remained unchanged by TTA
treatment (Fig. 5g).
Fig. 2 Dietary treatment for
2 weeks with TTA affects
hepatic fatty acid composition
and changes saturated fatty
acids (a), monounsaturated fatty
acids (b), n-3 polyunsaturated
fatty acids (c), and n-6
polyunsaturated fatty acids
(d) levels signiﬁcantly. The data
is given as weight % of total
fatty acid ± S.D. (n = 5).
* denotes statistical signiﬁcant
differences to the control by
Student’s t test (P\0.05). SFA
saturated fatty acids, MUFA
monounsaturated fatty acids,
PUFA polyunsaturated fatty
acids, TTA tetradecylthioacetic
acid
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Obesity-related metabolic disorders are associated with a
state of chronic low-intensity inﬂammation. Inﬂammation
induces a wide array of metabolic changes in the body and
affects expression of many proteins involved in lipid
metabolism. The different subtypes of the nuclear ligand-
dependent transcription factors, PPAR, play key roles in
lipid homeostasis. They are involved in the regulation of
lipoprotein metabolism, fatty acid oxidation, glucose and
carnitine homeostasis and also seem to be involved in
inﬂammatory processes [39]. TNFa is one of the factors
that mediate alterations in lipid metabolism, including
decreased PPARa mRNA and protein levels [40]. With the
knowledge in mind that previous studies have shown that
the biological response to TTA treatment is at least partly a
result of PPAR activation, and that this bioactive fatty acid
analogue has the ability to activate all three isoforms of
PPAR [21, 23, 41], as well as increase the mRNA level of
PPARa [42], we wanted to test if TTA was able to coun-
teract TNFa-induced metabolic aberrations.
In the present study we demonstrated that TTA, in
addition to its health-promoting effects in previous in vivo
[43] and in vitro experiments [26, 44], could also amelio-
rate several parameters in a mouse model of chronic
inﬂammation. TNFa might induce hypertriglyceridemia,
characterized by the accumulation of very low density
lipoprotein (VLDL) in the plasma, due to impaired removal
of VLDL [45] and increased hepatic lipogenesis [46].
TAG-rich lipoproteins were shown to be important for the
acute phase response by binding to endotoxins to reduce
their harmful action [47]. However, systemic low-grade
inﬂammation with elevated circulating levels of TNFa seen
in obese subjects is typically associated with high plasma
TAG levels that will increase the risk for metabolic and
cardiovascular complications [48]. It is therefore of
importance to note that TTA has the capability to strongly
reduce plasma TAG levels in a chronic inﬂammatory state
with persistently high TNFa levels.
The observation of decreased TAG in the plasma is
compatible with the hypothesis that there is a higher ﬂux of
fatty acids from the plasma to the liver, with a
Table 2 Comparison of hepatic
fatty acid composition in control
and TTA treated hTNFa
transgenic mice
The anti-inﬂammatory index is
calculated as described in
Experimental Procedure. The
ratio of C20:4n-6 to C20:3n-6
gives an indirect index of the
n-6 D5 desaturase activity. The
data are given as weight
% ± S.D. (n = 5). A two
sample, two-tailed t-test
assuming equal variance was
calculated. NS means not
signiﬁcant
Fatty acid control TTA Level of signiﬁcance
SFA
C15:0 0.07 ± 0.002 0.03 ± 0.001 P\0.0001
C16:0 21.42 ± 0.35 24.3 ± 0.204 P\0.0001
C17:0 0.19 ± 0.012 0.10 ± 0.009 P\0.0001
C18:0 12.02 ± 0.554 6.42 ± 0.585 P\0.0001
C22:0 0.15 ± 0.017 0.07 ± 0.016 P\0.0001
C23:0 0.08 ± 0.004 0.03 ± 0.004 P\0.0001
C24:0 0.11 ± 0.009 0.05 ± 0.006 P\0.0001
MUFA
C16:1 0.02 ± 0.003 0.01 ± 0.001 P\0.002
C16:1n-7 1.03 ± 0.127 1.44 ± 0.291 P\0.03
C18:1n-7 1.6 ± 0.079 1.72 ± 0.23 NS
C18:1n-9 21.77 ± 0.748 35.22 ± 1.796 P\0.0001
C20:1n-9 0.26 ± 0.022 0.49 ± 0.064 P\0.0001
n-6 PUFA
C18:2n-6 16 ± 0.540 9.90 ± 0.743 P\0.0001
C20:4n-6 12.96 ± 0.788 8.61 ± 0.628 P\0.0001
C20:3n-6 0.9 ± 0.059 2.51 ± 0.291 P\0.0001
n-3 PUFA
C18:3n-3 0.42 ± 0.027 0.13 ± 0.010 P\0.0001
C18:4n-3 0.04 ± 0.005 0.01 ± 0.002 P\0.0001
C22:6n-3 7.60 ± 0.646 4.49 ± 0.431 P\0.0001
C20:5n-3 0.29 ± 0.028 0.27 ± 0.043 NS
Anti-inﬂammatory index 70.12 ± 2.883 88.94 ± 4.551 P\0.0002
C20:4n-6/C20:3n-6 14.41 ± 1.429 3.46 ± 0.380 P\0.0001
C18:1n-9/C18:0 1.81 ± 0.117 5.54 ± 0.752 P\0.0001
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123simultaneous reduction in fatty acid biosynthesis. But even
though TTA up-regulates hepatic mitochondrial CPT-I and
ACS activities, accompanied by an increase in hepatic
b-oxidation and plasma carnitine levels, it is not sufﬁcient
to deal with the already existing high TAG levels in the
transgenic mice. It is noteworthy that TTA has the capa-
bility to downregulate the hepatic biosynthesis of fatty
acids, since the FAS activity is reduced by 27% in the TTA
treated animals. Reduced lipogenesis and increased fatty
acid oxidation after TTA treatment seem to be the reason
for decreased plasma TAG levels by 54% after TTA
treatment. Yet, the exact reasons why hepatic TAG were
not affected similarly by TTA are not yet elucidated at the
molecular level and will require further detailed studies. It
might be that a higher dose of TTA is required to get a
more pronounced effect on lipogenesis, thereby inﬂuencing
hepatic TAG levels. Previously, we have found indications
that the effect on hepatic TAG metabolism may be dose
dependent and that the amount of hepatic TAG is decreased
with increasing doses of TTA [49]. It could also be that a
longer feeding period than the two weeks applied is needed
to overcome hepatic TAG accumulation. Noteworthy is
that we have never detected a TTA-induced liver steatosis
in any of the mouse or rat models used previously. It is
however of importance to verify in future studies if
increasing amounts of TTA could counteract this effect in
the mouse model used and if this ﬁnding is of signiﬁcance
for humans.
The increased hepatic phospholipid level that we
measure in the TTA treated group, is probably a conse-
quence of increased membrane production due to mito-
chondrial and peroxisomal proliferation as seen after
TTA treatment previously [50–52]. Moreover, adminis-
tration of PPARa ligands has been described to lead to
hepatic hypertrophy and hyperplasia leading to increased
liver weights as seen in our study. The liver enlargement
is however restricted to rodents and has never been
described in humans [53–58].
By measuring plasma free carnitine and its acyl-esters,
in particular the two most abundant species, acetyl car-
nitine and propionyl carnitine, we looked at overall
changes in the b-oxidation process. We found that
plasma free carnitine levels were increased due to TTA
administration, as well as the short- and medium-chain
carnitine esters, but not long-chain fatty acyl carnitines. It
is important to note that in addition to being essential for
transport of fatty acids into mitochondria, carnitine is
crucial to increase acyl and acetyl group export out of
mitochondria into the blood [59]. By increasing carnitine
levels through TTA administration, lipotoxicity of
b-oxidation metabolites is reduced and mitochondrial
capacity is improved. The excess short-chain acyl-esters,
that cannot be used by the TCA cycle, will be secreted in
urine. The formation of trimethyllysine and its conversion
to c-butyrobetaine is reported to occur in most tissues,
but the last step in carnitine biosynthesis, the hydroxyl-
ation of c-butyrobetaine to carnitine, occurs only in liver
and kidney in mice. Therefore interorgan transport of
c-butyrobetaine and carnitine are of importance. It was
of interest that plasma c-butyrobetaine levels were
decreased, whereas carnitine levels were increased. This
may be due to increased consumption of c-butyrobetaine
for carnitine biosynthesis and increased mitochondrial
oxidation of long-chain fatty acids.
TTA affects the capacity for insertion of double bonds
and counteracts the abnormal hepatic fatty acid compo-
sition levels under the inﬂuence of TNFa. Correct pro-
portions of fatty acids are crucial to maintain cellular
Fig. 3 Palmitoyl-CoA b-oxidation is increased in liver mitochondria
of TTA-treated mice (a) and the sensitivity for inhibition of oxidation
of palmitoyl-CoA with malonyl-CoA (given in % inhibition) is lower
in the TTA group compared to high fat-fed controls (b). Oxidation of
palmitoyl-CoA was measured in puriﬁed mitochondria as acid-soluble
products. Bars indicate ± S.D. (n = 5). * P\0.05 different from the
control. Palm-CoA, palmitoyl-CoA; TTA, tetradecylthioacetic acid
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123functions, a balance that was disturbed in the TNFa
transgenic mice. hTNFa overexpression was accompanied
by increased saturated and polyunsaturated fatty acids,
but decreased levels of monounsaturated fatty acids in
liver [18]. The basic values of these fatty acid families in
hTNFa control group in our high fat diet experiment
compared to the previous study were less pronounced,
which could be partially attributed to a different diet in
[18] (low fat standard mouse chow with 26 % SFA, 25
% MUFA, 4 % PUFAn-3 and 45 % PUFAn-6). Never-
theless, it did not affect the trends of fatty acid changes
inside the dietary groups (high fat diet and standard chow
diet, respectively). Moreover, TTA reduced the n-6 D5
desaturase activity index in transgenic mice as fatty acid
saturation was increased. This was accompanied by
decreases of n-3 and n-6 polyunsaturated fatty acids
including stearidonic acid (C18:4n-3) and docosahexaenoic
acid (C22:6n-3), as well as linoleic acid (C18:2n-6) and
arachidonic acid (C20:4n-6). The amount of arachidonic
acid is of importance for the calculation of the anti-
inﬂammatory fatty acid index, and decreased amounts after
TTA treatment increased the fatty anti-inﬂammatory index
in this group. Saturated fatty acids, that have pro-inﬂam-
matory and insulin-antagonizing properties [60], were
decreased by TTA, thereby lowering the risk for the
development of metabolic syndrome. On the other hand,
monounsaturated fatty acids were increased after TTA
treatment. This is potentially beneﬁcial, as high levels were
associated with low rates of cardiovascular disease [61].
Another risk factor for cardiovascular disease in humans is
low HDL-cholesterol due to its important function in
reverse cholesterol transport to the liver [62]. We found
elevated plasma HDL-cholesterol levels with an increase of
63% in TTA treated TNFa transgenic mice. However, in a
study including a small group of HIV-infected patients, we
found that TTA in combination with dietary intervention
can reduce total cholesterol, LDL-cholesterol, and
LDL/HDL cholesterol, but no increase in HDL-cholesterol
could be observed [63]. It has been shown previously that
apolipoprotein compositions and responses to PPARa
activation are different between humans and rodents [64,
65]. The result of increased HDL-cholesterol in hTNFa
overexpressed mice in our study might therefore be rodent-
speciﬁc. However, effects of PPARa activation on other
pathways of lipid metabolism including FA uptake and
activation, b-oxidation, and lipogenesis support similarities
between mice and humans [39]. This suggests similar
responses upon TTA treatment in humans as seen in our
mice study.
In summary, given the ability of TTA to increase b-oxi-
dation, reduce plasma TAG, and positively affect hepatic
saturated and monounsaturated fatty acid compositions
Fig. 4 Enzyme activities of the
mitochondrial enzymes CPT-I
(a) and ACS (b) involved in
b-oxidation are increased in the
liver of hTNFa transgenic mice
treated with TTA, whereas the
cytosolic FAS activity involved
in biosynthesis of fatty acids
shows reduced activity after two
weeks of treatment (c). Values
are means ± S.D. (n = 5) and
* shows a P\0.05 difference
from the control. CPT-I,
carnitine palmitoyl transferase I;
ACS, acyl-CoA synthetase;
FAS, fatty acid synthase; TTA,
tetradecylthioacetic acid
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123leading to an increase in the anti-inﬂammatory fatty acid
index, indicates that TTA has a high potential to ameliorate
chronic inﬂammation such as with obesity, arthritis or
atherosclerosis.
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Fig. 5 A change in plasma
levels of free carnitine (a),
trimethyllysine (b),
c-butyrobetaine (c), acetyl
carnitine (d), propionyl
carnitine (e), octanoyl carnitine
(f), and palmitoyl carnitine
(g) could be detected after TTA
treatment. * denotes statistical
signiﬁcant differences by
Student’s t-test between control
(grey bars) and TTA (white
bars)( P\0.05) and bars
indicate ± S.D. (n = 5)
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